2025
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
Ranzani O, Lazar Neto F, Mareto L, Brumatti T, de Oliveira R, da Silva P, Dos Santos E, D' Agostini T, De Paula R, Dean N, Ko A, Cummings D, Andrews J, Hitchings M, Croda J. Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study. The Lancet Infectious Diseases 2025 PMID: 40845862, DOI: 10.1016/s1473-3099(25)00382-2.Peer-Reviewed Original ResearchAcute febrile illnessCase-control studyTAK-003Vaccine effectivenessSymptomatic dengueFirst doseSecond doseFebrile illnessDengue vaccineReal-world evidenceTest-negativeDays of symptom onsetTetravalent dengue vaccinePublic health challengeHigh-transmission settingsLogistic regression modelsDengue virus serotype 1National surveillance databaseSao PauloRT-PCR testHealth challengesSymptomatic diseaseGlobal health threatNS1 antigenSurveillance database
2019
Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region
Rodriguez-Barraquer I, Costa F, Nascimento EJM, Nery N, Castanha PMS, Sacramento GA, Cruz J, Carvalho M, De Olivera D, Hagan JE, Adhikarla H, Wunder EA, Coêlho DF, Azar SR, Rossi SL, Vasilakis N, Weaver SC, Ribeiro GS, Balmaseda A, Harris E, Nogueira ML, Reis MG, Marques ETA, Cummings DAT, Ko AI. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 2019, 363: 607-610. PMID: 30733412, PMCID: PMC8221194, DOI: 10.1126/science.aav6618.Peer-Reviewed Original ResearchConceptsZika virusZIKV NS1 antigenAttack rateZika virus emergenceHigh antibody titersDengue-endemic regionsZIKV immunityClinical outcomesDengue immunityZIKV infectionAntibody titersNS1 antigenRisk factorsEndemic regionsDengue virusImmunityVirusRiskVirus emergenceFuture transmissionCohortSymptomsInfectionAntigenTiters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply